Sign up online today & collaborate
or click here to find out more
04 May 2016, London, UK: OBN – the membership organisation supporting the UK’s innovative life sciences companies – announces today that BioTrinity, its annual conference and 10th edition this year, has once again confirmed its position as Europe’s leading investment and biopartnering conference, with 1020 delegates present, building on its growing momentum and success in the sector.
John Harris, CEO of OBN, commented on this year’s event : “For its 10th edition, BioTrinity has been a fabulous success. The large number of delegates from across Europe, with a record number of investors and extremely high calibre panellists, confirms BioTrinity’s position as a key meeting in the European life sciences calendar. We would like to thank all our sponsors and speakers and already look forward to the 11th edition in 2017.”
The success of BioTrinity 2016 is demonstrated by the outstanding statistics:
Scott C. Brun, Vice President, Corporate Strategy Office at AbbVie Ventures, comments: “AbbVie is proud to be a sponsor of the BioTrinity 2016 investment and biopartnering conference. Our team found the meeting to be an effective way to network with proven investors and cutting edge entrepreneurs in order to strengthen relationships and jointly identify emerging science with the potential to transform care in our core areas of oncology, immunologic, and neurodegenerative diseases.”